EML4 and non-small cell lung carcinoma: Although the available evidence on the association between variant types and treatment outcomes in the ALEX clinical trial is limited, patients treated with alectinib demonstrate superior response and improved survival compared to those treated with crizotinib in treatment-naive patients with ALK-positive NSCLC, irrespective of the EML4-ALK variant.